3 Canadian AI Healthcare Stocks With Revenue Up To $19 Million

Big tech just reminded investors that heavy AI spending can weigh on near term profits, after Alphabet reported weaker than expected search revenue and a hit to free cash flow from AI costs. That kind of warning shot makes Canadian healthcare AI especially interesting. The focus is narrower, the use cases more concrete, and the payoffs often easier to understand. This article highlights three screen picks riding that trend.

The three stocks covered below are just a sample, and the full screen surfaced 3 more AI healthcare companies with equally detailed narratives that are not included in this article. To go straight to the broader opportunity set, analyze and compare potential high conviction ideas inside the Transformative Artificial intelligence (AI) Healthcare Stocks screener.

Telescope Innovations (CNSX:TELI)

Telescope Innovations is a CA$24 million chemical technology business that develops tools like its DIRECTINJECT-LC reactor and analytics platform, which is designed for AI-driven reaction monitoring and process optimization in pharmaceutical and chemical manufacturing. It currently generates about CA$7.3 million from chemicals-focused activities.

Telescope Innovations gives AI healthcare investors a way to play the plumbing behind smarter drug manufacturing, since its AI-ready DIRECTINJECT-LC reactor system is built for real time reaction data and process tuning that pharma R&D can feed into machine learning models. The appeal depends on how that capability translates into adoption pressure inside drug production lines.

That adoption question is the real hinge, and the analysis report for Telescope Innovations reveals how Telescope Innovations' current operations align with that AI manufacturing thesis before momentum truly shows up.

Profound Medical (TSX:PRN)

Profound Medical develops AI-powered, MRI-guided systems like TULSA-PRO for incision-free ablation of prostate and other soft tissue, a direct play on automated image-guided therapy. The business generated about $19 million from medical technology and carries a market value of roughly CA$296 million.

Profound Medical plugs directly into the AI healthcare theme through TULSA-PRO, which uses MRI imaging, real-time temperature feedback and supervised robotic control to target prostate tissue with minimal cutting. That same AI-heavy control stack is now backed by fresh TDC software, PSMA-PET integration work and clinician education efforts, with future demand shaped by how one quiet reimbursement and adoption hinge resolves.

That reimbursement hinge is exactly what the 1 key reward and 1 important warning sign to see how Profound Medical’s upside and pressure points could be pulling in opposite directions.

Perimeter Medical Imaging AI (TSXV:PINK)

Perimeter Medical Imaging AI develops optical coherence tomography imaging systems for real time tissue margin viewing in the operating room, including Claire OCT with ImgAssist that applies AI analysis during breast conserving surgery. The business generated about $2 million from medical imaging systems and carries a market value near CA$24 million.

Perimeter Medical Imaging AI aligns with the Transformative AI Healthcare theme through Claire OCT with ImgAssist, which applies AI to live breast cancer surgery margins. Early commercial deployment and modest $2 million revenue currently make this a higher risk story, as future demand could change significantly depending on one unresolved adoption question.

That adoption hinge is exactly what the analysis report for Perimeter Medical Imaging AI unpacks, so you can see whether Perimeter Medical Imaging AI’s early traction matches the surgical use case that investors are betting on.

Seeking Alternatives Before The Crowd?

Fresh ideas move first. By the time a breakout is flying, the ideal entry can be gone. Scan these curated lists while it still matters and get in early.

• Spot cash generative outliers before momentum stories fully catch attention by reviewing the 38 profitable AI stocks that aren't just burning cash. Do not wait until every headline catches up.
• Line up potential compounders with sturdy finances by scanning the list of solid balance sheet and fundamentals (6 results). Strong foundations can matter most when sentiment starts dropping.
• Target potential yield workhorses while they are still under the radar for now by leaning on the 3 dividend fortresses. Let the income case come to you.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com